Ardelyx (ARDX) reported $125.22 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 7.8%. EPS of $0 for the same period compares to $0.02 a year ago.
The reported revenue represents a surprise of +6.51% over the Zacks Consensus Estimate of $117.57 million. With the consensus EPS estimate being $0.02, the EPS surprise was -100%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ardelyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $114.4 million versus the five-analyst average estimate of $114.14 million. The reported number represents a year-over-year change of +3.1%.
- Product sales- IBSRELA: $86.6 million versus the five-analyst average estimate of $85.75 million. The reported number represents a year-over-year change of +60.8%.
- Product sales- XPHOZAH: $27.8 million compared to the $28.39 million average estimate based on five analysts. The reported number represents a change of -51.4% year over year.
- Revenues- Licensing: $0.02 million compared to the $0.02 million average estimate based on three analysts. The reported number represents a change of +4.6% year over year.
- Non-cash royalty revenue related to the sale of future royalties: $1.35 million compared to the $3.66 million average estimate based on three analysts. The reported number represents a change of +47.4% year over year.
View all Key Company Metrics for Ardelyx here>>>
Shares of Ardelyx have returned -15.9% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ardelyx, Inc. (ARDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
